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Abstract
Zoledronic acid (ZOL) is the most potent nitrogen-containing bisphosphonate (N-BPs) that strongly binds to bone mineral and acts as a power-
ful inhibitor of bone resorption, already clinically available for the treatment of patients with osteolytic metastases. Recent data also suggest that
ZOL, used in breast cancer, may provide more than just supportive care modifying the course of the disease, though the possible molecular
mechanism of action is still unclear. As breast cancer is one of the primary tumours with high propensity to metastasize to the bone, we investi-
gated, for the first time, differential gene expression profile on Michigan Cancer Foundation-7 (MCF-7) breast cancer cells treated with low
doses of ZOL (10 lM). Microarrays analysis was used to identify, describe and summarize evidence regarding the molecular basis of actions of
ZOL and of their possible direct anti-tumour effects. We validated gene expression results of specific transcripts involved in major cellular pro-
cess by Real Time and Western Blot analysis and we observed inhibition of proliferation and migration through 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and Matrigel assay. We then focused on changes in the cytoskeletal components as fibronectin 1 (FN1),
actin, and anti angiogenic compounds as transforming growth factor-b1 (TGF-b1) and thrombospondin 1 (THBS1). The up-regulation of these
products may have an important role in inhibiting proliferation, invasion and angiogenesis mediated by ZOL.
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Introduction
Breast cancer is the most frequently diagnosed cancer in women
around the world and bone is its most common associated site of
metastasis [1]. ZOL is a potent N-BPs, inhibitor of bone resorption
that reduces the risk of skeletal complications and prevents treat-
ment-induced bone loss [2]. In oncology, its role in metastatic bone
disease is well established [3], but there is increasing interest in its
potential role in preventing and treating cancer-induced bone loss and
its possible anti-tumour effects [4].
N-BP shave been shown to inhibit the mevalonate pathway involved
in the synthesis of cholesterol, through inhibition of the enzyme farne-
syl diphosphate synthase. This process leads to the decreased produc-
tion of the isoprenoid lipids farnesyl diphosphate and geranyl geranyl
diphosphate both enzymes required for the prenylation of small GTP-
ases, such as Rho, Rac, cdc42 and Rab. Small GTP-ases signalling reg-
ulates key cellular processes including proliferation, cell motility, angio-
genesis, survival and migration, all mechanisms implicated in the
development and spreading of many types of cancer including breast
cancer [5–8]. Bisphosphonates, ZOL in particular, induce also tumour
cell apoptosis and stimulate cd T cell cytotoxicity against tumour cells.
In vivo, ZOL inhibits bone metastasis formation and reduces skeletal
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tumour burden in mouse models. This may reflect direct antitumour
effects and indirect effects via inhibition of bone resorption. In addition,
ZOL inhibits experimental angiogenesis in vitro and in vivo [9]. Data
from in vitro and pilot studies suggest that ZOL reduces circulating lev-
els of vascular endothelial growth factor (VEGF) in metastatic breast
cancer patients [10, 11], suggesting these drugs could interfere with
tumour-associated angiogenesis. Evidence in vivo already exists that
ZOL treatment inhibits tumour-associated angiogenesis by inducing a
profound reduction in macrophages infiltrating mammary or cervical
carcinoma lesions, associated with decreased VEGF and matrix metal-
loprotease-9 (MMP-9) levels in the tumour microenvironment [12].
Interactions of cells with their surroundings can have profound influ-
ences on gene expression and cellular behaviour [13–15].
Angiogenesis and regulation of tumour environment is essential for
cancer growth and progression, and therefore, anti-angiogenesis is one
promising strategy to treat cancer [16]. Numerous anti-angiogenic fac-
tors have been described as transforming growth factor b-1 (TGF-b1)
and relative TGF-b1/SMAD (small mother against decapentaplegic) sig-
nalling pathway plays an important role in cancer cells and leads to
growth inhibition, differentiation and apoptosis [17]. The TGF-bs repre-
sents a family of multifunctional cytokines that modulate the growth
and function of many cells, including those with malignant transforma-
tion. Their signalling pathways are frequently involved in suppressing
the growth of human tumours [18]. Recent data suggest that activation
of the TGF-b pathway leads to the induction of apoptosis closely fol-
lowed by the induction of cytostasis, resulting in different carcinoma
regression [19, 20]. An important natural activator of TGF-b1 is Throm-
bospondin 1 (THBS1), a trimeric glycoprotein strongly bound to the
extracellular matrix (ECM) [21] and a potent natural inhibitor of angio-
genesis [22]. Its ability to block migration of endothelial and cancer
cells in vitro has been shown to be independent of the activation of
TGF-b1 [23, 24]. THBS1 affects ECM structure and function both
through direct interactions and indirect effects on other components
that are secreted by the cell [25]. Consider that cell adhesion to ECM is
crucial to several steps in tumour progression and metastasis, many
studies have demonstrated that THBS1 mediates cellular adhesion of
numerous cell types and several transformed cell lines [24, 26]. Inhibi-
tion of angiogenesis is also a consequence, in part, of re-organization
of the actin cytoskeleton and disassembly of focal adhesions in endo-
thelial cells and to inhibit cellular motility, cellular migration and inva-
sion [27].The molecular and physical composition of the ECM can be
affected by tumour cells themselves, as well as multiple stromal cell
types. Alterations in the expression of ECM-related genes have been
identified in gene expression signatures related to poor prognosis and
metastases in breast cancers. Indeed, changes in the cytoskeletal com-
ponents such as production and organization of fibronectin (FN1), actin
and collagen have been implicated in eliciting the transition from dor-
mancy to metastatic growth [3, 28–32].
Consequently, we studied the potential mechanisms by which
ZOL may regulate global gene expression profile, cellular proliferation,
invasion and angiogenesis in MCF-7 breast cancer cells, an ideal
model of bone metastatizing cells [33], centering our discussion on
FN1, actin, TGF-b1 and THBS1, proteins with a central role respec-
tively on cytoskeletal re-organization, cellular motility, invasion and
angiogenetic process.
Materials and methods
Cell culture
Human breast cancer cell lines, MCF-7, purchased from the American
Type Culture Collection (Rockville, MD, USA) were grown in Dulbecco’s
modified Eagle’s medium Gibco DMEM:F12 (Invitrogen, Carlsbad, CA,
USA) containing 10% foetal bovine serum (FBS) and 1% Penicillin/
Streptomycin (P/S) (Gibco). Cells were incubated at 37°C in a humidi-
fied atmosphere of 5% of CO2. Eighty per cent confluent cultures were
stimulated with either 10 lM of ZOL for 24, 48 and 72 hrs. ZOL was
kindly provided by Novartis Pharma AG. The stock solution of ZOL was
prepared at a concentration of 4 mg/ml in distilled water, and aliquots
were stored at 20°C.
Cell growth assays
Seventy per cent confluent cultures were treated with 10, 50 and
100 lM of ZOL. Cell numbers before and after 1, 2 and 3 days of treat-
ment were determined by counting the cells. All assays were done in
triplicate and repeated at least twice.
Cell viability assay
Cell viability in human breast cancer cell lines, MCF-7, treated with 10,
50 and 100 lM of ZOL for 24 hrs, was determined by 3-(4,5-dim-
ethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as pre-
viously described in literature [34] with minor modifications. Briefly,
MCF7 cells were seeded in flat-bottomed 96-well plates at a density of
10,000 cells/well. Twenty-four hrs later, growing cells were washed and
treated for 24 hrs with the ZOL (10 and 100 lM). Cell viability was
measured using MTT at a concentration of 0.5 mg/ml (20 ll/well). After
1 hr incubation at 37°C, cells were solubilised in DMF (Dimethyl form-
amide) solution (DMF/H2O, 1:1, pH 4.7) containing 20%SDS for an
additional incubation time of 16 hrs at 37°C to dissolve the blue forma-
zan product. Optical density was measured at 570 nm using a 96-well
plate reader (EL800; Biotek Instruments, Winooski, VT, USA). All the
experiments were run in sextuplicate and repeated twice.
Microarray analysis
Total cellular RNA was isolated from MCF-7 cells treated with ZOL
(10 lM) for 24 hrs using the miRNeasy Mini Kit (Qiagen Inc, Valencia,
CA, USA) and quantified through 2100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA). Five micrograms of total RNA was reverse
transcribed using the high capacity cDNA archive kit (Applied Biosys-
tems, Foster City, CA, USA) according to vendor’s instructions.
Then cDNAs were in vitro transcribed for 16 hrs at 37°C using the IVT
Labelling Kit (Affymetrix) to produce biotinylated cRNA. Labelled cRNA
was isolated using the RNeasy Mini Kit column (QIAGEN). Purified cRNA
was fragmented to 200–300 mer using a fragmentation buffer. The qual-
ity of total RNA, cDNA synthesis, cRNA amplification and cRNA fragmen-
tation was monitored by capillary electrophoresis (Bioanalizer 2100;
Agilent Technologies). Fifteen micrograms of fragmented cRNA was hy-
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bridised for 16 hrs at 45°C with constant rotation, using a human oligo-
nucleotide array U133 Plus 2.0 (Genechip; Affymetrix, Santa Clara, CA,
USA). After hybridization, chips were processed using the Affymetrix
Gene Chip Fluidic Station 450 (protocolEukGE-WS2v5_450). Staining
was made with streptavidin-conjugated phycoerythrin (SAPE) (Molecular
Probes), followed by amplification with abiotinylated anti-streptavidin
antibody (Vector Laboratories, Burlingame, CA, USA), and by a second
round of SAPE. Chips were scanned using a Gene Chip Scanner 3000 G7
(Affymetrix) enabled for High-Resolution Scanning. Images were
extracted with the Gene-Chip Operating Software (Affymetrix GCOS
v1.4). Quality control of microarray chips was performed with the Af-
fyQCReport software [35]. A comparable quality between microarrays
was demanded for all microarrays within each experiment.
Microarray statistical analysis
The background subtraction and normalization of probe set intensities
was performed with the method of Robust Multi array Analysis
described by Irizarry et al. [36]. To identify differentially expressed
genes, gene expression intensity was compared using a moderated test
and a Bayes smoothing approach developed for a low number of repli-
cates [37]. To correct for the effect of multiple testing, the false discov-
ery rate was estimated from P-values derived from the moderated t-test
statistics [38]. The analysis was performed with the affylmGUI Graphical
User Interface for the limma microarray package [39].
Matrigel invasion assay
The invasive potential of breast cancer cells was assessed in vitro in
matrigel-coated invasion Chambers (BD BioCoat Matrigel Invasion
Chamber; Becton Dickinson Biosciences, Franklin Lakes, NJ, USA) in
accordance with the manufacturer’s instructions. Cell invasion experi-
ments were performed with a 24-well companion plate with cell culture
inserts containing 8 um pore size filters. Untreated MCF-7 cells and
drug-treated MCF-7 cells with ZOL 10 lM for 24 and 48 hrs (5 9 104/
500 ll) were added to each insert (upper chamber), and the chemoattr-
actant (FBS) was placed in each well of a 24-well companion plate
(lower chamber). After 22 hrs incubation at 37°C in a 5% CO2 incuba-
tor, the upper surface of the filter was wiped with a cotton-tipped appli-
cator to remove non-invading cells. Cells that had migrated through the
filter pores and attached on the under surface of the filter were fixed
and stained by Diff-Quik staining kit (BD, Becton Dickinson Biosciences,
San Jose, CA, USA). The membranes were mounted on glass slides,
and the cells from random microscopic fields (940 magnification) were
counted. Five fields per membrane were randomly selected and counted
in each group. All experiments were run in duplicate, and the percent-
age of invasive cells was calculated as the percentage invasion through
the matrigel membrane relative to the migration through the control
membrane, as described in the manufacturer’s instructions.
Real time-quantitative PCR (Q-PCR)
Total cellular RNA was isolated from MCF-7 cells treated with ZOL
(10 lM) for 24hrs using the miRNeasy Mini Kit (Qiagen Inc) and quan-
tified through 2100 Bioanalyzer (Agilent Technologies). Five micrograms
of total RNA was reverse transcribed using the high capacity cDNA
archive kit (Applied Biosystems), according to vendor’s instructions.
Five microlitre of the RT products was used to amplify FN1
(hs01549976_m1), ACTIN (hs99999903_m1), TGF-b1 (hs00998133)
and Trombospondin 1 (THBS1) (hs00962914) sequences using the Taq-
Man gene expression assay (Applied Biosystems). To normalize quanti-
tative real-time PCR reactions, parallel TaqMan human Cyclophilin
(4326316E) control reagents assays (Applied Biosystems) were run on
each sample. Changes in the target mRNA content relative to control
mRNA were determined using a comparative Ct method to calculate
changes in Ct, and ultimately fold and percent change. An average CT
value for RNA was obtained by reactions in triplicate.
Western blotting (WB)
The cells were treated with 10 lM ZOL for 24, 48, 72, and also 96 hrs or
left untreated, and then were lysed to obtain total proteins using com-
plete Lysis-M reagent (Roche, Mannheim, Germany)Protein concentra-
tion was determined by the Bradford method and the expression of
proteins was analyzed in 150 lg of total protein lysates. Proteins were
separated on a gel with 8 and 10% polyacrylamide under denaturing con-
ditions and transferred by electrophoresis to a nitrocellulose membrane.
Nonspecific binding was blocked by soaking membranes in 1 9 TBS,
5% powdered milk, and 0.05% Tween-20 for at least 60 min. at room
temperature. Membranes were incubated with the following primary anti-
bodies: p44/42 MAPK (Erk1/2) mouse mAb# 9107 (at 1:2000), Phospho-
p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) Rabbit mAb #4377 (at
1:2000), Akt1 (2H10) Mouse mAb #2967 (at 1:100) and Phospho-Akt
(Ser473) (193H12) Rabbit mAb #4058 (at 1:1000) were from Cell Signal-
ling Technology, Fibronectin antibody, Rabbit polyclonal antibody to FN1
GTX112794 (at 1:1000), beta Actin [AC-15] antibody, mouse monoclonal
GTX26276 (at 1:5000) and TGF beta [TB21] antibody, mouse monoclonal
GTX21279 (at 1:1000) were from Gene Tex, Inc. (Irvine, CA, USA),
Smad4 (MAB1132 at 1 lg/mL) and anti-Smad2/3 (#07-408 at 1:500)
were from Millipore Corporation (Vimodrone MI, Italy), THBS1 mouse
monoclonal and GAPDH (6C5): sc-32233 were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). After the membranes were washed three
times with TBS plus 0.05% Tween-20 for 30 min., they were incubated
with the following peroxidase (HRP)-conjugated secondary: anti-rabbit,
anti-mouse and anti-goat antibody (2030; Santa Cruz Biotechnology)
diluted to 1:1000, followed by three washes with TBS plus 0.05% Tween-
20. Detection was performed with chemiluminescence detection reagents
(ECL; Pierce Biotechnology Inc., Rockford, IL, USA).
Results
ZOL inhibit breast carcinoma cells proliferation
To identify the lower dose of ZOL sufficient to induce an anti-prolifer-
ative effect on MCF-7 cell proliferation, we tested different concentra-
tions (10–100 lM) of ZOL for 24, 48 or 72 hrs.Cell count showed
that cell growth was inhibited by ZOL versus control at all concentra-
tions used (Fig. 1). In particular, tumour cell growth was reduced to
about 40% at a ZOL concentration of 100 lM over a period of incuba-
tion of 24 hrs whereas the lower ZOL concentration (10 lM) was
slightly less efficient (20%), but effective. Consider that inhibition
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rates of 10 and 100 lM of ZOL were not shown a significant
difference, we can assert that the treatment at lower concentration for
only 24 hrs is sufficient to induce an inhibition of proliferation, also
confirmed by determination of number of metabolically active cells
by MTT assay (Fig. 1A and B). On the basis of these data, we
have selected this concentration of ZOL for all the subsequent experi-
ments.
To elucidate the mechanisms by which cell proliferation is sup-
pressed, we have analysed the effects of ZOL on specific proliferative
pathways. Time-course experiments were performed using WB to
determine phosphorylation and thus activation of MAPK and AKT
pathways. We found that phosphorilation of MAPK and AKT was
decreased significantly after both 24 hrs and 48 hrs exposure to
10 lM ZOL (Fig. 2).
Thus, as expected and previously reported with higher doses
[40], also low doses of ZOL induced decrease of both MAPK and Akt
activity, by which ZOL inhibits the cell proliferation and the ability of
tumour cells to expand once they colonize bone [41–44].
Gene expression profile of MCF-7 breast cancer
cells treated with low doses of zoledronic acid
The main aim of this study was to investigate the molecular mecha-
nisms by which low doses of ZOL exert their antitumour effects in
breast cancer cells. Though ZOL have clearly demonstrated to inhibit
proliferation and induce apoptosis in cancer cell lines by interfering
with the mevalonate pathway [5–8], the type and pattern of down-
stream genes modulated by ZOL treatment are still unknown.
To investigate molecular basis of anti-tumoural effect of low
doses of ZOL on breast cancer cells, we have evaluated the expres-
sion profiling of MCF-7 treated with 10 lM of ZOL for 24 hrs versus
untreated, using a cDNA microarray platform Affymetrix. Of the
33,000 independent features on the microarrays, 126 were found to
be differentially expressed after 24 hrs of treatment. In particular, 17
genes were downregulated (1.57 to 2.88), and 109 genes were
upregulated (+1.52 a +5.27). For following analysis we considered
only the genes with fold change >2 and with statistical difference of
expression of each gene was at least P < 0.001 (Fig. 3A).
We grouped genes related to biological process, molecular func-
tion categories and finally in cellular component categories, that have
changed in a statistically significant manner (P-value  0.05) after
treatment with ZOL (Fig. 3B–D). The most significant changes in bio-
logical processes confirmed the involvement of ZOL in metabolic pro-
cesses, in fact 38 genes are differentially regulated. Other changes
were observed in the cellular localization (24 genes regulates), cell
communication (20 genes regulated) and in cell proliferation path-
ways (eight genes) (Fig. 3B).
Analysis also showed a regulation of molecular function catego-
ries, as protein (37 genes) and ion binding (27 genes), and trans-
porter activity (11 genes) affected by ZOL (Fig. 3C). Cellular
Fig. 1 A, B ZOL inhibits cell growth in vitro. About 105 and 104 cells
were cultured in 6-well and 96-well tissue culture plates and exposed to
ZOL at a concentration ranging from 10 to 100 lM for different times.
Cellular viability was analyzed by cellular count (A) and MTT assay (B).
Fig. 2 Effects of ZOL addition on MAPK and Akt-dependent pathways on
MCF-7 cells. Cells were treated with 10 lM ZOL for 24, 48, 72 and
96 hrs. Thereafter, both the expression and activity of MAPK p44/42
and AKT were evaluated. Determination of the expression and phos-
phorylation of MAPK p44/42 and AKT evaluated as described in Materi-
als and methods. Expression of the house-keeping protein GAPDH,
used as loading control.
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Fig. 3 (A) Treatment with ZOL globally
affects gene expression profile in MCF-7
cells. (B, C, D) Corrected microarray sig-
nal values of genes involved in different
biological process, clustered by specific
functions (Biological process, Cellular
function, Cellular component) of MCF-7
cells treated for 24 hrs with 10 lM ZOL
in comparison to control cells.
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component categories that result differentially regulated by gene
expression profile included components of membrane and cytoskele-
tal (48 genes), nucleus (19 genes) and of endoplasmic reticulum (13
genes) (Fig. 3D).
Alterations in gene expression identified by microarray analysis
show modification of possible early-response genes as the treatment
with ZOL was carried out for only 24 hrs, and were further investi-
gated by real-time quantitative reverse transcription-PCR.
Effects of ZOL on breast carcinoma cells
invasion
In light of previous observation, we hypothesized that the inhibitory
effect of ZOL on cellular growth and deregulation of cytoskeletal com-
ponent observed by analysis of gene expression, could result in inhi-
bition of tumour cell invasion. To address this question, alterations in
gene expression, identified by microarray analysis, were further
investigated by real-time quantitative reverse transcription-PCR and
WB analysis to investigate whether alterations in gene expression
were translated into corresponding changes in protein levels.
We found that treatment with ZOL induces transcription and pro-
tein expression of some matrix and cytoskeletal components, such
as Fibronectin and actin, involved in cancer microenvironment. In
particular, the up-regulation of gene coding for FN1 shown by
microarray (fold change of 1.93) was confirmed by Real Time RT-
PCR with a fold change of 2.3 compare with control (Fig. 4A) and
mRNA expression of actin, analysed by Real time RT-PCR, showed a
fold change of 1.5. Interestingly, a high protein expression is main-
tained even at longer treatment (at 96 hrs), and with the most acti-
vating effect in the protein products, indicating the potential
consequences of ZOL treatment on the morphology and cell motility,
considered the cellular roles of FN1 and actin as factors that can
change the ECM (Fig. 4B).
Then, the effects of ZOL, on the in vitro invasion of MCF-7 were
investigated by Matrigel assays. We observed that cells treated even
with only 10 lM of the drug, resulted in a reduction in invasion in a time
dependent manner, reaching 60–90% inhibition after 24 hrs (Fig. 5).
These results demonstrate that ZOL treatment has a strong inhibi-
tory effect not only on MCF-7 cells growth but also on invasiveness
and that possibly the alteration of FN1 and actin expression, could be
involved in invasion of human breast cancer cell lines.
ZOL increases expression of anti angiogenetic
factors in breast carcinoma cell lines
ZOL can inhibit angiogenesis of tumour cells and emerging evidence
suggests that the use of this agent may impede the development of
bone metastases [45, 46].THBS1, TGF-b1 and its signalling effectors
regulate many aspects of tumour cell biology, such as growth arrest
and cell motility, the latter of which is important for the metastatic
dissemination of tumour cells from their primary location to lymph or
blood vessels [47–49].
To investigate the effects on angiogenesis induced by low dose of
ZOL, we observed specific mRNA expression and protein levels of
TGF-b1and THBS1, to confirm overexpression observed by micro-
arrays analysis, in particular, TGF-b1showed a fold change of +2.3
and THBS1 a fold change of +2.6 compare with untreated control.
After only 24 hrs exposed to ZOL, both transcription and protein
expression was significantly increased (Fig. 6), indicating possible
implication of these two protein in anti-angiogenetic process medi-
ated by low doses of ZOL.
Moreover, as classic TGF-b signalling involves the activation of
Smad2/3 and Smad4, direct mediators that accumulate into the
nucleus, we examined Smad expression using WB method. Smad
complexes interact with transcription factors, co-activators and co-
repressors where they participate in the regulation of different target
gene expression [50].
Treated MCF-7 cells exhibited a substantial increase in Smad 2/3
at 24 hrs whereas Smad4 peaked at 24 hrs and began to decrease
Fig. 4 Effect of ZOL on the mRNA expression and protein levels of FN1
and ACTIN. (A) Effect of ZOL 10 lM on the mRNA expression of FN1
and ACTIN, as quantified by real time PCR in MCF-7 cells. (B) Effect of
ZOL on FN1 and ACTIN protein levels. MCF-7 cells were incubated with
low concentration of ZOL for different times, and protein expression
were examined by Western blot developing with the enhanced chemo-
luminescence reagent (ECL). Each membrane was also probed with
GAPDH to confirm equal loading.
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after 72 hrs (Fig. 7), indicating that MCF-7 cells possibly contain suf-
ficient quantities of receptors and Smads to signal in response to
TGF- b 1 (Fig. 7).
Fig. 5 ZOL decrease the invasive potential of human breast cancer cells.
Effect of ZOL on the invasion of MCF-7 cells. Treated or not with ZOL
10 lM for 24 hrs, were plated onto Matrigel invasion chambers as
described in Materials and methods, and the cell invasion was evalu-
ated. The invaded cells for each insert were stained and quantified. The
results are expressed as a percentage of MCF-7 not treated cells (B).
The experiments were performed at least three different times, and the
results were always similar. Data are represented as percentage of con-
trol (100%).
Fig. 6 Effect of ZOL on the transcript and protein levels of THBS1 and
TGFb1. A. mRNA expression of THBS1 and TGFb1, as quantified by real
time PCR in MCF-7 cells treated. (B) Effect of ZOL on THBS1 and
TGFb1 protein levels. MCF-7 cells were incubated with low concentra-
tion of ZOL for different times, and protein expression were examined
by Western blot. The house-keeping protein GAPDH was used as load-
ing control. The experiments were performed at least three different
times, and the results were always similar.
Fig. 7 Effects of ZOL on TGF-b1-dependent pathway and Smad protein
expression. Cells were treated with 10 lM ZOL for 24, 48, 72 and
96 hrs. Determination of the expression SMAD2/3 and SMAD4 evalu-
ated after blotting with specific antibodies, as described in Materials
and methods. Expression of the house-keeping protein GAPDH, used as
loading control. The experiments were performed at least three different
times, and the results were always similar.
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Discussion
Preclinical studies have demonstrated that ZOL can inhibit proliferation,
invasion, migration and angiogenesis of tumour cells. Emerging evi-
dence also suggests that the use of this agent may impede the develop-
ment of bone metastases in mouse models [45, 46]. The mechanism
by which ZOL exerts its anti-cancer properties have already been inves-
tigated, and its direct effect on cancer cells, as well as the inhibitory
effect on tumour angiogenesis, has been confirmed [51, 52]. Several
studies have demonstrated that, in vitro, the binding of breast and pros-
tate cancer cells to bone surfaces is inhibited by ZOL, that this treatment
also has an inhibitory effect on cell proliferation and that a decrease of
cellular migration was observed when prostate and breast cancer cell
lines were cultured with ZOL [4, 53, 54]. This mechanism seems to be
mediated by the effects on the cytoskeleton through Rho A [5].
The main aim of our study was to investigate the molecular mech-
anisms by which ZOL exerts its antitumour effects in breast cancer
cells by Microarray analysis.
To identify the lower dose of ZOL sufficient to induce a moderate
anti-proliferative effect on MCF-7 cell proliferation, we first performed
cell proliferation assays, by cellular count and MTT. We tested different
concentrations (10-100 lM) of ZOL for 24, 48 or 72 hrs, and we found
that the highest inhibitive rate reached to nearly 50%. Considering that
10 lM of ZOL had shown a sufficient inhibitory effect, we have
selected this concentration of ZOL for all the subsequent experiments.
Data obtained from observation of the activation of major cellular
pathways are indicative of mechanisms by which this drug is able to
block cellular proliferation. In particular, we confirm, also with low
doses, the inhibition of the phosphorylation state of AKT and MAPK
protein [40], responsible for key cellular pathways.
To deeply investigate the molecular mechanism by which ZOL
acts as antitumour drug, we have performed a gene expression profil-
ing of MCF-7 breast cancer cells treated with low doses of ZOL, and
we have demonstrated that ZOL induce differential expression of 126
genes with a strongly up-regulation of different cytoskeletal and ECM
component. Based on these results, we also hypothesized that low
concentrations of ZOL may affect the processes of invasiveness in
cancer cells by altering their ability to invade the tumour microenvi-
ronment and thus inhibit their metastatic potential.
As tumour cell invasion requires both cell migration and digestion
of the basement membrane, we hypothesized that ZOL inhibited MCF-
7 tumour cell invasion was mostly dependent on the cell surface
activity driven by FN1 expression and on remodelling of cytosckeletal
components. Several studies suggest that FN1 is related to tumour
invasion and metastasis [55, 56] playing a key role in the tissue
remodelling and cell migration events that occur during normal devel-
opment; it has been thought to have an important role in both tumour
invasion and metastasis. In particular, FN1 is a major constituent of
the cell surface of many cultured cells, and it is either eliminated or
reduced on the surface of oncogenically transformed cells [55]. Many
reports have suggested that there is a correlation between the loss of
cell surface FN1 and the ability of a cell to metastasize [44].
In our study, after treatment with10 lM of ZOL, FN1 and actin
result up-regulated both by Real Time RT-PCR and WB, indicating their
possible involvement in cytoskeletal re-organization induced by ZOL.
On the basis of these considerations, we have performed a Matri-
gel assay of MCF-7 breast cancer cells treated with ZOL at 10 lM for
24 hrs, and we have demonstrated that ZOL strongly inhibits invasion
of these cells. These data agreed with some earlier research in vitro
[18, 56]. However, the regulatory mechanism of FN1 expression of
breast carcinoma is not clear. It is thought it could be regulated by a
variety of growth factors such as TGF-b1 frequently involved in sup-
pressing the growth of human tumours [18].
In fact our analysis confirmed that ZOL treatment have induced an
up-regulation of transcription and of protein product of TGF-b1, letting
us to speculate its involvement in transcriptional control of FN1. As
classic TGF-b signalling involves the activation of Smad2/3 and Smad4,
we also demonstrated that ZOL induce, at 24 hrs, an increase of
Smad2/3 and Smad4 as direct mediators of TGF-b signalling in final
activation of anti angiogenetic effects of ZOL. ZOL can also inhibit
angiogenesis of tumour cells and emerging evidence suggests that the
use of this agent may impede the development of bone metastases
[45, 46].
We also found that low dose of ZOL, increased expression of
THBS1, a factor involved in the angiogenesis process [55, 56], but
also in the regulation of FN1 and actin. THBS1, TGF-b1 and its signal-
ling effectors regulate many aspects of tumour cell biology, such as
growth arrest and cell motility, the latter of which is important for the
metastatic dissemination of tumour cells from their primary location
to lymph or blood vessels [47, 48].
Finally, our results suggested that ZOL showed anti-proliferative
and anti-invasive effects in MCF-7 cells and that these data may
depend on the activator effect of ZOL in the expression of ECM,
cytoskeletal component, and anti-angiogenc factors found in this
study. On the basis of this preliminary results in vitro, it could be
interesting to develop molecular therapeutic strategies based on the
specific activation of the expression of particular component for inhi-
bit tumoural growth and angiogenesis, or to evaluate in particular
specific roles of FN1 and actin, blocking their expression, in inducing
effect antiproliferative and anti-invasive of ZOL in human breast
cancer cells.
This study strongly encourage the new experimental design for
treatment of breast cancer based on administration of ZOL and to dis-
cover their target molecular in cancer cells for future more effective
synergistic treatments.
In conclusion, in the present studies, we investigated the role of
ZOL in the regulation of breast cancer cell invasion. Our results dem-
onstrated that ZOL, via cytoskeletal remodelling, plays an inhibitory
role in breast cancer cell invasion, possibly by specifically up-regulat-
ing the TGF-b1/Smad signalling pathway, and the downstream activity
of FN1 and ACTIN.
On the basis of these results, future work has been hypothesized,
it could be interesting to develop molecular therapeutic strategies
based on the specific regulation of expression and/or function of
cytoskeletal components.
Therefore in future works, will be evaluated the activity of ectopic
regulation of FN1 mRNA expression to study effective potential anti-
proliferative and anti-invasive of ZOL in human breast cancer cells,
focusing on the other factors or protein families that influence inva-
sive potential of MCF-7 tumour cells.
ª 2012 The Authors 2193
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Finally, these data strongly encourage the design of clinical trials
based on the concomitant administration of ZOL and ectopic addi-
tional expression of matrix proteins for efficacy testing.
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